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Abstract
Host response to RNA virus infection is sensed by RNA sensors such as RIG-I, which induce 
MAVS-mediated NF-κB and IRF3 activation to promote inflammatory and antiviral responses, 
respectively. Here, we found that CARMA3, a scaffold protein previously shown to mediate NF-
κB activation induced by GPCR and EGFR, positively regulates MAVS-induced NF-κB 
activation. However, our data suggest that CARMA3 sequesters MAVS from forming high-
molecular weight aggregates, thereby suppressing TBK1/IRF3 activation. Interestingly, following 
NF-κB activation upon virus infection, CARMA3 is targeted for proteasome-dependent 
degradation, which releases MAVS to activate IRF3. When challenged with Vesicular stomatitis 
virus or Influenza A virus, CARMA3-deficient mice showed reduced disease symptoms compared 
to those of wild type mice due to less inflammation and stronger ability to clear infected virus. 
Together, our studies reveal the role of CARMA3 in regulating the balance of host anti-viral and 
pro-inflammatory responses against RNA virus infection.
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Graphical abstract
Jiang et al. revealed that CARMA3, a gene located in a host genomic locus that contributes to the 
host susceptibility to RNA respiratory virus infection, is a key molecule that controls the balance 
of pro-inflammatory and anti-viral responses through positively regulating NF-κB activation but 
negatively regulating IRF3 activation.
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Introduction
The innate immune system is the first line of host defense against infection, which is 
essential for initial detection and recognition of pathogens, activation of acute anti-microbial 
responses, and subsequent activation of adaptive immunity. This system utilizes pattern 
recognition receptors (PPR), such as Toll-like receptors (TLRs) on the cell surface and 
cytosolic RIG-I-like receptors (RLRs) to detect the invading pathogen (Baum and Garcia-
Sastre, 2011; Janeway, 2013; Jiang et al., 2011a). The RLR family of proteins is crucial for 
detecting viral RNA in cytosol. It is composed of retinoic acid-inducible gene 1 (RIG-I), 
melanoma differentiation-associated protein 5 (MDA5) and laboratory of genetics and 
physiology 2 (LGP2). RIG-I senses 5′-triphosphate RNA as well as short (<2 kbp) dsRNA 
and is essential for innate immunity to many ssRNA viruses, including influenza A virus 
(IAV), Sendai virus (SeV), respiratory syncytial virus (RSV), Vesicular Stomatitis Virus 
(VSV), etc. In contrast, MDA5 recognizes longer dsRNA (>2kb) and protects host from 
infection of Encephalomyocarditis virus (EMCV), Theiler's virus, mengovirus, murine 
norovirus, and murine hepatitis virus (Kato et al., 2006; McCartney et al., 2008; Roth-Cross 
et al., 2008).
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Without stimulation, RIG-I is in the closed conformation with the N-terminal CARD 
domains bound to the central helicase domain. Upon binding of the CTD to viral RNA, RIG-
I undergoes conformational changes, oligomerization, and exposure of the CARD domains 
to recruit a signaling adaptor called mitochondrial antiviral-signaling protein (MAVS). 
MAVS contains a N-terminal CARD domain, a proline-rich region and a transmembrane 
domain (TMD) at the C-terminus. The CARD domain is important for its interaction with 
upstream RLRs (Goubau et al., 2014; Kawai et al., 2005; Meylan et al., 2005; Seth et al., 
2005; Xu et al., 2005). The proline-rich region is required for the recruitment of multiple E3 
ligases such as TNF receptor-associated factors (TRAFs). The TMD domain is key for 
MAVS localization at the mitochondrial outer membrane. Upon activation, MAVS forms a 
functional prion-like structure at mitochondria and works as a platform to form a MAVS 
signalosome that further activates IKKα/IKKβ/NEMO signaling and TBK1/IKKε/NEMO 
signaling (Liu et al., 2013).
Activation of IKKα/IKKβ/NEMO triggers activation of transcription factors NF-κB and 
thus induction of pro-inflammatory cytokines (Liu and Gu, 2011). These cytokines are 
important to induce inflammatory responses and to restrict viral replication and spread 
(Dienz et al., 2012). Elevated levels of pro-inflammatory cytokines are closely correlated 
with severity of clinical diseases, including airway inflammation and acute lung injury 
during influenza infection in children (Chiaretti et al., 2013). On the other hand, activation 
of the TBK1/IKKε/NEMO complex leads to activation of IRF3 and production type I 
interferon (IFN), including IFNα and IFNβ (Fitzgerald et al., 2003; Sankar et al., 2006; 
Zhong et al., 2008). Type I interferon are potent inducers for the expression of hundreds of 
interferon-stimulated genes (ISGs) in paracrine and autocrine fashions, which induce a 
cellular anti-viral state on the target cells (Au et al., 1995; Schafer et al., 1998; Sun et al., 
2010). Recent mechanistic studies have found that, upon activation, MAVS forms a prion-
like fibril at mitochondria, and acts as an active platform for the recruitment of E3 ligases, 
including TRAF6, TRAF2 and TRAF5, through distinct TRAF binding domains (Hou et al., 
2011; Liu et al., 2013; Xu et al., 2014). These E3 ligases are essential for signaling 
downstream of MAVS, regulate the polyubiquitination chains, and recruit downstream 
IKKα/IKKβ/NEMO complex and TBK1/IKKε/NEMO complex (Liu et al., 2013).
It has been an important question why different individuals display highly variable systemic 
symptoms across the infected populations during outbreaks of seasonal virus infection. In 
order to study how genetic polymorphisms contribute to this variation, Ferries et al crossed 
different incipient lines of mice, which exhibit a broad range of susceptibility to influenza A 
virus (IAV) infection, and identified three novel quantitative trait loci (QTL) that may 
contribute to the susceptibility for IAV infection (Ferris et al., 2013). One of these QTLs, 
Hrl4, contains 13 genes (Ferris et al., 2013). Among these genes, most of them do not have a 
clear link to the antivirus response, except for CARD10 gene (Ferris et al., 2013), which 
encodes a scaffold protein also named CARMA3 (Jiang and Lin, 2012).
CARMA3 contains multiple protein-protein interaction domains, including a N-terminal 
CARD domain, a coiled-coil domain, and a C-terminal MAGUK domain (Gaide et al., 2001; 
Jiang and Lin, 2012). CARMA3 is expressed only in non-hematopoietic cells, while 
CARMA1, a related protein, is expressed only in hematopoietic cells. The CARMA proteins 
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share similar structure and functions, albeit with distinct tissue distribution. Upon activation, 
CARMA proteins form a complex with B-cell lymphoma 10 (BCL10) and caspase-like 
protein MALT1 (mucosa-associated lymphoid tissue lymphoma translocation protein 1), and 
the CARMA-BCL10-MALT1 (CBM) complex functions to activate the downstream IKK 
complex, leading to activation of NF-κB (Jiang and Lin, 2012). Previous studies have shown 
that CARMA3 is crucial in mediating GPCR- and EGFR-, but not TLR- or TNFR-, induced 
NF-κB activation (Grabiner et al., 2007; Jiang et al., 2011b; Klemm et al., 2007; McAllister-
Lucas et al., 2007). However, it is unknown whether CARMA3 is also involved in regulating 
the host responses to viral infection.
It is known that virus infection induces robust NF-κB activation in host cells to trigger 
expression of pro-inflammatory cytokines, which help inhibiting virus replication and spread 
in host. Since CARMA3 is located in the genomic locus that contributes to host 
susceptibility to viral infection, and is involved in NF-κB signaling, we investigated its role 
in host anti-viral response. Our data suggest that CARMA3 contributes to inflammatory and 
antiviral responses via regulating RIG-I/MAVS-induced TBK1/IRF3 and NF-κB activation. 
We have found that CARMA3 deficiency results in the defect in VSV- and RNA-induced 
NF-κB activation and production of pro-inflammatory cytokines, but surprisingly, enhanced 
TBK1/IRF3 activation and production of type I interferon, thereby displaying a reduced viral 
load in VSV-infected cells and tissues. Mechanistic studies showed that CARMA3 inhibited 
IRF3 activation through blocking the formation of MAVS aggregation. Together, these 
results reveal that CARMA3 is a key molecule that regulates the balance between RNA virus 
infection-induced inflammatory and anti-viral innate immune response.
Results
CARMA3 negatively regulates host antiviral responses
Recent genetic studies indicate that CARD10 gene is located in the genomic locus that may 
contribute to the host susceptibility to IAV infection(Ferris et al., 2013). To explore the 
biological significance of CARMA3 in host antiviral response, we challenged wild type 
(WT) and CARMA3-/- (KO) mice with IAV strain PR8, a strain that has been highly 
adapted in mice and cause disease symptoms and mortality in mice. IAV infection caused a 
significant body weight loss of WT mice, but not that of CARMA3 KO mice (Fig. 1A). Viral 
yield was much higher in lungs of WT mice than those of CARMA3 KO mice at 2 days 
post-infection (Fig. 1B). Similarly, lung injury caused by IAV infection was greatly 
attenuated in CARMA3 KO mice (Fig. S1A), suggesting that CARMA3 plays a negative 
role in anti-viral response against IAV infection. Consistently, we found that CARMA3 KO 
mice produced more type I interferon IFNβ in lungs compared to WT mice (Fig. 1C), but 
expressed less pro-inflammatory cytokines IL-6, IL-1α, and IL-1β following IAV infection 
(Fig. 1D, and S1B-D), suggesting that CARMA3 also plays a positive role in inflammation 
in response to influenza virus infection.
Vesicular stomatitis virus (VSV) is another negative sense, single-stranded RNA virus, and 
its infection induces a flu-like symptom as IAV does. To examine whether CARMA3 also 
contributes to the host responses to VSV infection, we challenged WT and CARMA3 KO 
mice intranasally with VSV. Since VSV is a neurotropic virus, and brain is one of primary 
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targeting tissues of VSV, we examined the viral load in brain of these mice. Interestingly, we 
found that viral loads were significantly higher in the olfactory bulbs (OB) of the brain in 
WT mice than that in CARMA3 KO mice (Fig. 1E-F), although smaller difference was 
found in spleen and lung of these mice (Fig. S1E-F). Consistent with the low viral load in 
CARMA3 KO mice, we found that CARMA3 KO mice produced significantly higher levels 
of local IFNβ in OB (Fig. 1G), whereas the expression of IFNγ and G-CSF in the brain of 
WT and CARMA3 KO mice was similar (Fig. S1G-H). Similar to the response to IAV 
infection, we found that production of pro-inflammatory cytokines, such as IL-6, IL-1α, 
IL-1β, and TNFα, in the sera of CARMA3 KO mice was significantly reduced than that in 
WT mice 2 days following VSV infection (Fig. S1I-M). Together, these results further 
support above observations that CARMA3 plays a negative role in regulating antiviral 
responses in the host, but it plays a positive role in regulating the expression of pro-
inflammatory cytokines in response to viral infection.
CARMA3 regulates RIG-I/MAVS-mediated IKK/NF-κB activation in vitro
Since CARMA3 is only expressed in non-hematopoietic cells, the observed effect of 
CARMA3 deficiency on viral infection in vivo might be compromised by the contribution of 
hematopoietic cells. To reveal the molecular mechanism by which CARMA3 affects 
inflammatory and antiviral response to virus infection, we prepared primary WT and 
CARMA3 KO MEF cells and stimulated these cells with VSV. Consistent to the in vivo 
data, we found that VSV infection in WT MEF cells induced significantly higher levels of 
IL-6 mRNA and protein than that in CARMA3 KO MEF cells (Fig. 2A-B). Since IL-6 is a 
well-known target of NF-κB, we examined the NF-κB activation, and found that NF-κB 
activation was partially defective in CARMA3 KO MEF cells following VSV stimulation 
(Fig. 2C).
It has been shown that dsRNA virus infection can induce NF-κB through both TLR 
signaling and RIG-I/MAVS signaling. Given the fact that CARMA3 is not required for TLR- 
induced NF-κB activation(Grabiner et al., 2007), we hypothesize that CARMA3 only 
mediates RIG-I/MAVS-induced NF-κB, which can explain why VSV-induced NF-κB was 
only partial defective in CARMA3 KO cells. To test this hypothesis, we stimulated WT and 
CARMA3 KO MEF cells with RIG-I-specific ligands poly(I:C) or 5′ triphosphate double 
stranded RNA (5′ppp-dsRNA). Consistently, we found that NF-κB activation and 
production of IL-6 were severely defective in CARMA3 KO MEF cells in response to these 
stimuli (Fig. 2D-F and Fig. S2A-B). Furthermore, we immortalized CARMA3 WT and KO 
MEF cells and reconstituted the KO cells with HA-tagged CARMA3 to its endogenous level 
(Fig. S2C). This reconstitution of CARMA3 rescued the phenotypes (Fig. 2G-J). To find out 
if this is also the case in other cell types, we used BEAS-2B cells, a primary and 
immortalized human lung epithelial cell line, by knockdown of CARMA3 expression via 
shRNA (Fig. S2D), and consistent data were observed (Fig. 2K-L).
CARMA3 regulates RIG-I/MAVS-mediated TBK1/IRF3-IRF7 activation in vitro
Type I interferon such as IFNα and IFNβ are important antiviral cytokines that are induced 
by RIG-I/MAVS-mediated activation of TBK1-IRF3 signaling. We found that VSV infection 
induced significantly higher levels of IFNβ mRNA and protein in CARMA3 KO MEF cells 
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than that in WT MEF cells (Fig 3A-B). Consistently, IRF3 phosphorylation at S396 and 
TBK1 phosphorylation was induced at higher levels in CARMA3 KO MEF cells at 6 and 8 
hours following VSV infection (Fig. 3C). To determine if this observation is specific for 
viral infection, we stimulated these cells with RIG-I specific ligands, 5′triphosphate double 
stranded RNA (5′ppp-dsRNA) or poly(I:C). Consistently, production of IFN and IRF3 
activation is enhanced in CARMA3 KO MEF cells (Fig. 3D-F, and Fig. S3A-E). 
Furthermore, the virus load was reduced in CARMA3 KO MEF cells, compared to that of 
WT MEF cells (Fig. 3G).
To further confirm above data, we reconstituted CARMA3 KO MEF cell with either a 
CARMA3 expression plasmid or a control vector. We found that the phenotypes observed in 
CARMA3 KO MEFs were reverted in CARMA3-reconstituted KO MEF cells (Fig. 3H-K). 
Consistently, knockdown of CARMA3 in human lung epithelial cells (BEAS-2B) rendered 
stronger TBK1/IRF3 phosphorylation and the higher expression level of type I interferon 
following VSV infection (Fig. 3L-M and S3F). Furthermore, we isolated primary lung cells 
from CARMA3 WT and KO mice, and higher IFNβ was detected in the CARMA3 KO lung 
cells, compared to that of WT cells (Fig. S3G), although we were not able to detect any 
significant difference in IL-6 production, which is likely due to the high basal level of IL-6 
production in these cells (Fig. S3H).
BCL10 regulates RIG-I/MAVS-mediate NF-κB and IRF3 activation in vitro
Previous studies have shown that BCL10 and MALT1 bind to CARMA3 to form CARMA3-
BCL10-MALT1 (CBM) complex upon EGFR and GPCR induced NF-κB activation 
(Grabiner et al., 2007; Jiang et al., 2011b; Klemm et al., 2007; McAllister-Lucas et al., 2007; 
Wang et al., 2007a). Next, we would like to determine if BCL10 and MALT1 play a similar 
function as CARMA3 in response to virus infection. Similar to CARMA3 deficiency, 
BCL10 deficiency led to reduced expression of IL-6 but enhanced expression of IFNβ, and 
higher level of IRF3 phosphorylated upon VSV infection or poly(I:C) treatment in primary 
MEF cells (Fig. 4A-E). Consistently, we observed reduced viral load in olfactory bulbs (OB) 
of BCL10 KO mice, compared to that of WT mice (Fig. 4F). These results indicate that 
BCL10 plays a similar role as CARMA3 in response to virus infection.
However, MALT1 deficiency did not result in defective IL-6 production (Fig. S4A). 
Although IFNβ expression was slightly increased in MALT1 KO MEF cells (Fig. S4B), 
IFNα expression was similar to that in WT MEF (Fig. S4C-D). Consistently, viral infection-
induced NF-κB activation was not significantly changed in MALT1 KO MEF cells (Fig. 
S4E). Although IRF3 phosphorylation was slightly enhanced in MALT1 KO MEF cells (Fig. 
S4F), it was not as significant as what observed in CARMA3 KO or BCL10 KO MEF cells. 
Together, these data suggest that MALT1 does not play a dominant role in regulating viral 
infection-induced NF-κB and IRF3 activation.
CARMA3 regulates RIG-I/MAVS-mediated IKK/NF-κB activation and TBK1/IRF3 activation in 
an independent manner
Interestingly, we found that VSV infection-induced NF-κB activation could be detected as 
early as the first hour post-infection, whereas IRF3 phosphorylation was not detectable until 
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4 hours post-infection (Fig. 2C and 3C). Since VSV infection-induced NF-κB activation was 
partially defective but IRF3 activation was enhanced in CARMA3 KO MEF cells, we 
decided to examine whether NF-κB-targeted genes expressed at early time points post-
infection might inhibit IRF3 activation. To test this possibility, wild type MEF cells were 
pre-treated with NF-κB nuclear translocation inhibitor (NF-κBi) for 1 hour before VSV 
infection. Although NF-κBi pretreatment partially inhibited NF-κB activation (Fig. 5A), it 
did not enhanced but, instead, partially inhibit IRF3 phosphorylation (Fig. 5B), indicating 
that it is not NF-κB-inducing genes suppressing IRF3 phosphorylation. To further support 
this conclusion, we transfected IkBα super-repressor (SR) mutant into immortalized MEF 
cells, and found that although expression of IkBα SR mutant could suppress VSV-induced 
NF-κB activation, it could not enhance IRF3 phosphorylation (Fig. 5C-D). Finally, to 
determine whether newly synthesized proteins regulate IRF3 activation, primary MEF cells 
were pretreated with protein synthesis inhibitor cycloheximide (CHX) before poly(I:C) 
transfection. Pre-treatment of cycloheximide did not alter IRF3 activation (Fig. 5E). 
Therefore, the impaired NF-κB activation at early hours post-infection is not the cause for 
the enhanced IRF3 activation in CARMA3 KO MEF cells, indicating that CARMA3 
regulates NF-κB and IRF3 activation through an independent event.
CARMA3 and BCL10 regulates RIG-I/MAVS signaling by binding to MAVS
To determine the molecular mechanism by which CARMA3 and BCL10 regulate viral 
infection-induced NF-κB and IRF3 activation, CARMA3 or BCL10 was knocked down by 
shRNA in HEK293T cells. Overexpression of MAVS induced robust expression of NF-κB-
dependent and IRF3-dependent luciferase reporters in control cells, whereas defective NF-
κB activation and enhanced IRF3 activation were observed in CARMA3 or BCL10 
knockdown cells (Fig. 5F, 5I, and S5A). However, when TBK1 or IKKε was overexpressed 
in these cells, knockdown of CARMA3 or BCL10 did not alter activation of NF-κB or IRF3 
(Fig. 5G-H, 5J-K and S5B-C), indicating that CARMA3 and BCL10 function downstream 
of MAVS, but upstream of TBK1 and IKKε.
Since CARMA3 is a scaffold protein with multiple protein-protein interacting domains, we 
examined whether CARMA3 is physically associated with MAVS. When overexpressed in 
HEK293T cells, CARMA3 bound to MAVS, but only weakly to RIG-I (Fig. 6A), whereas, 
BCL10 interacted with both MAVS and RIG-I (Fig. S6A). In contrast, MALT1 could not 
bind to MAVS when overexpressed in HEK293T cells (Fig. S6B). Furthermore, endogenous 
MAVS was capable to interact with overexpressed CARMA3 or BCL10 in HEK293T cells 
(Fig. 6B). More interestingly, inducible interactions, but not constitutive interactions were 
observed between endogenous MAVS and BCL10, or between endogenous MAVS and 
CARMA3 in CARMA3-reconstituted KO MEF cells (Fig. 6C-D). The dynamic interaction 
between MAVS and CARMA3 could be detected in both primary BCL10 Het and KO MEF 
cells (Fig. 6E), whereas the MAVS-BCL10 interaction could only be detected in CARMA3 
KO cells reconstituted with CARMA3 but not with its vector control (Figure 6F). These data 
suggested BCL10 might be recruited to the MAVS containing complex via CARMA3, but 
not vice versa. To address whether CARMA3 binds to MAVS through CARD-CARD 
interaction, we co-transfected HEK293T cells with MAVS and CARMA3 WT or truncate 
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mutants (Fig. S6C-D). We found that the C-terminal GUK domain, but not the CARD 
domain, of CARMA3 appeared to be critical for the binding to MAVS.
CARMA3 and BCL10 regulate RIG-I/MAVS signaling by disrupting MAVS aggregation
It has been showed that infection of Sendai virus (SeV), another negative, single-stranded 
virus, induces the formation of large MAVS aggregates, which is functionally important in 
mediating IRF3 activation (He et al., 2014; Hou et al., 2011; Moresco et al., 2011; Xu et al., 
2014). Since CARMA3 binds to MAVS, we hypothesized that CARMA3 may block MAVS 
oligomerization. When CARMA3 was over-expressed together with RIG-I in HEK293T 
cells, CARMA3 was detected in the mitochondria fraction in a dose-dependent manner (Fig. 
7A). In contrast, only a very small fraction of RIG-I was isolated together with mitochondria 
(Fig. 7A). This suggests that CARMA3 can be recruited to mitochondria, and bind to 
MAVS. Importantly, overexpression of CARMA3 was able to disrupt the formation of 
endogenous MAVS aggregates in SDD-AGE gel, which is 2% SDS-resistant, (Fig. 7A). This 
is also the case for BCL10 (Fig. S7A-B). To further confirm that CARMA3 blocks MAVS 
forming aggregates, we infected primary MEF cells with VSV and isolated crude 
mitochondria. We observed significantly stronger formation of endogenous MAVS 
aggregates in CARMA3 KO MEF cells at 6 hours post infection (Fig. 7B), and consistently, 
this stronger aggregation of MAVS in CARMA3 KO cells could be reverted when a 
CARMA3 was reconstituted back into the CARMA3 KO MEF cells (Fig. 7C). Together, 
these results indicate that CARMA3 plays a negative role in the assembly of MAVS 
aggregates upon virus infection.
CARMA3 is targeted for ubiquitination and proteasome degradation
Due to the lack of anti-CARMA3 antibody suitable for detecting endogenous CARMA3 
protein by immunoblotting, we generated stable cells that express HA-tagged CARMA3 in 
CARMA3 KO MEF cells. Interestingly, we found that HA-tagged CARMA3 protein was 
gradually reduced upon VSV infection (Fig. 7D-G). However, this reduction in CARMA3 
protein was rescued by pre-treatment of cells with proteasome inhibitor MG132 (Fig. 7E-F). 
This indicated that following VSV infection, CARMA3 is targeted for proteasome 
degradation. Therefore, we performed immunoprecipitaion with anti-HA agarose, and found 
that a high amount of K48 ubiquitinated CARMA3 was observed in the presence of MG132 
at 4 hours post infection of VSV (Fig. 7F). However, in contrast to CARMA3, the protein 
level of BCL10 was not significantly altered following VSV infection (Fig. 7G). Together, 
these results suggest that CARMA3 is targeted to proteasome-mediated degradation 
following RNA virus infection.
Discussion
In this study, we reveal that CARMA3 is a novel regulator of RIG-I/MAVS signaling. We 
have found that CARMA3 regulates RIG-I/MAVS-mediated NF-κB and TBK1/IRF3 
activation in a two-phase mechanism (Fig. S7C). Upon RIG-I activation, MAVS is first 
activated at early time points following viral infection, which can activate IKKα/IKKβ/
NEMO in CARMA3/BCL10-dependent manner. However, in this early phase of post 
infection, MAVS is sequestered by CARMA3/Bcl10 complex via interaction, and therefore, 
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it cannot form the high-molecular weight aggregates, which is required for downstream 
activation of TBK1/IRF3 signaling. With time, CARMA3 is targeted to a proteasome-
mediated degradation, which releases MAVS that forms the functional aggregates and 
activate TBK1/IRF3 signaling. Therefore, CARMA3 functions as a host factor to regulate 
the balance of the RIG-I/MAVS-induced two downstream signaling pathways for antiviral 
innate immune response and the pro-inflammatory response. On one hand, CARMA3 plays 
a positive role in MAVS-induced NF-κB activation, leading to induction of pro-
inflammatory cytokines, but on the other hand, it plays a negative role in MAVS-induced 
TBK1/IRF3 activation and production of antiviral cytokines, type I interferon (Fig. S7C). 
However, the precise mechanism how CARMA3 is targeted for ubiquitination-based 
proteasome degradation requires further investigation. In addition, it will be interesting to 
see if CARMA3 plays a general effect in response to other RNA viruses as well as DNA 
viruses that are typically not recognized by cytoplasmic RLRs.
Different individuals display highly variable systemic symptoms in response to viral 
infection. However, host factors contributing to this variability are largely unknown. Recent 
studies suggest that CARD10 gene, which encodes CARMA3, is located in a genomic locus 
that contributes to host susceptibility to RNA virus such as IAV infection (Ferris et al., 
2013). Our data, showing that the distinct regulation of CARMA3 in the pro-inflammatory 
response and antiviral response, suggest that CARMA3 may be a gene contributing to the 
host susceptibility to viral infection. Therefore, it will be important to find out whether 
CARMA3 protein expression levels or particular CARMA3 polymorphisms exist in different 
human populations, which may explain the variable susceptibility among different 
populations in response to virus infection.
CARMA3 is distinguished from many other mediators downstream of MAVS identified so 
far, which are either positive or negative mediators for both NF-κB activation and IRF3 
activation. These mediators include NEMO, TRAF6, A20, and CYLD (Friedman et al., 
2008; Liu et al., 2013; Maelfait et al., 2012; Parvatiyar et al., 2010; Saitoh et al., 2005; Zhao 
et al., 2007). In contrast, CARMA3 deficiency led to reduced NF-κB activation but increase 
in IRF3 activation. CARD9 is structurally related to CARMA3 and contains a CARD 
domain and a coiled-coiled domain, but no MAGUK domain. CARD9 is primarily expressed 
in myeloid cells. In bone marrow-derived dendritic cells (BMDCs), CARD9 deficiency 
resulted in defects in NF-κB activation and production of pro-inflammatory cytokines, 
including IL-6 and IL-1β, in response to 5′ppp dsRNA treatment; however, it did not alter 
production of type I interferon (Poeck et al., 2010). In addition to CARD9, CARMA1 is also 
expressed in myeloid cells. It will be interesting to find out how CARMA1, the counterpart 
of CARMA3 in hematopoietic cells, functions in mediating RIG-I/MAVS signaling in 
myeloid cells. In contrast to CARMA1, CARMA3, or CARD9, BCL10 is universally 
expressed. BCL10 functions similarly to CARD9 in BMDCs in response to 5′ppp dsRNA 
treatment, whereas in primary MEF cells, it functions similarly to CARMA3 upon VSV 
infection or poly(I:C) treatment. This suggests that BCL10 may regulate RIG-I/MAVS 
signaling in cell type specific manner.
During RNA virus infection, NF-κB activation can be induced through TLR-dependent and 
TLR-independent signaling pathways. It has been demonstrated that CARMA3 is not 
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required for TLR-induced NF-κB activation (Jiang et al., 2011b; Pan and Lin, 2013). In this 
study, we found CARMA3 deficiency induced only partial defects in NF-κB activation, 
suggesting that CARMA3 may play an important role in TLR-independent NF-κB 
activation, which is induced by RIG-I/MAVS signaling. TLR-dependent NF-κB activation 
may play dominant roles in induction of local IL-6 production in non-hematopoietic cells 
following RNA viral infection, which may explain why we do not observe significant effect 
of CARMA3 deficiency in local IL-6 mRNA production in OB following VSV infection.
Virus infection-induced NF-κB activation promotes expression of pro-inflammatory 
cytokines and chemokine, which are crucial to trigger inflammatory responses in the host. 
During viral infection, it is important to keep the inflammatory response under control to 
avoid severe tissue damage. Overly robust NF-κB activation or inflammation can lead to 
severe health consequences. For example, Ebola virus, a negative sense, single-stranded 
virus, is a highly virulent pathogen that causes a frequently lethal hemorrhagic fever 
syndrome, which is well correlated with the high inflammatory response that is induced in 
the host (Rasmussen et al., 2014). Therefore, it is important to regulate inflammatory 
response to a safe level to prevent severe tissue damage in such patients during viral 
infection. CARMA3 deficiency leads to a reduced NF-κB activation and production of pro-
inflammatory cytokines. Challenging wild type mice with IAV induced strong production of 
pro-inflammatory cytokines including IL-6, and severe inflammation, lung injury, and 
significant weight loss, which were attenuated in CARMA3 KO mice, indicating that 
CARMA3 is a key molecule to regulate inflammatory responses in the host and potentially a 
therapeutic target.
Previous studies indicate that NF-κB activation contributes to the production of type I 
interferon in response to viral infection (Basagoudanavar et al., 2011; Wang et al., 2010; 
Wang et al., 2007b). In this study, instead of observing a compromised production of type I 
interferon, we found even higher production of type I interferon in CARMA3 KO MEF 
cells. Therefore, the contribution of the enhanced IRF3 activation in the absence of 
CARMA3 not only counteracted the defect of NF-κB, but also resulted in greater overall 
production of IFNβ. This indicates the importance of CARMA3 on inhibiting the expression 
of type I interferon and antiviral responses, suggesting that IRF3 activation plays a more 
dominant role in the expression of type I interferon than NF-κB activation in response to 
RNA virus infection.
In this study, we find that CARMA3 functions downstream of MAVS, and upstream of 
TBK1 or IKKε. As a scaffold protein, CARMA3 interacts with MAVS and prevents the 
formation of high-molecular weight MAVS aggregates thereby blocking IRF3 activation. It 
is interesting that CARMA3 is gradually turned over following VSV infection, which may 
serve as a mechanism to turn off NF-κB activation, and meanwhile, it releases MAVS to 
form functional aggregates to induce IRF3 activation. Further studies are necessary to 
determine the molecular mechanism how CARMA3 is targeted for K48 ubiquitination and 
degradation, and targeting CARMA3 for degradation may help to reduce inflammation 
while enhancing the anti-viral response. Therefore, understanding this mechanism may 
provide molecular insights for designing therapeutic agents for suppressing viral infection-
induced inflammation.
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Experimental Procedures
Antibodies and reagents
Antibodies against Flag (sc-807), IkBα (sc-371), IKKα (sc-7218), HA (sc-7392), His 
(sc-803), BCL10 (sc-5611), Myc (sc-40), IRF3 (sc-9028), NEMO (sc-8330), β-actin 
(sc-8432), and α-tubulin (sc8035) were purchased from Santa Cruz Biotechnology. 
Antibodies against p-IkBα (9246), p-IKKα/β (2681), Caspase 3 (9664) p-IRF3 (4947), p-
TBK1 (5483), TBK1 (3013) were from cell signaling. The rabbit polyclonal antibody 
against Carma3 was home made against the peptide VRGRILQEQARLVWVEC, matching 
to the C terminus of human and mouse CARMA3. The anti-MAVS antibody was kindly 
provided by Dr. Zhijian J. Chen (UT Southwestern). Oligonucleotide probes for NF-κB 
(E3291) and OCT-1 (E3241) were purchased from Promega (Madison, WI). TRIzol 
(15596-026) and Superscript III First-Strand Synthesis system (18080051) were obtained 
from Invitrogen (Carlsbad, CA) and DNase I kits (10104159001) were purchased from 
Roche Applied Science (Indianapolis, IN). Two times SYBR Green PCR Master Mix was 
purchased from Applied Biosystems (Foster City, CA). Influenza A/PR/8/34(H1N1) was 
purchased from Charles River. NF-κBi and cycloheximide (CHX) were purchased from 
Sigma.
Cells
Cells were grown in DMEM medium (HEK293T, BHK and MEF) containing 10% FBS at 
37°C, 5% CO2 except for MEF cells, which were incubated at 37°C, 8.5% CO2. BEAS-2B 
cells were purchased from ATCC, cultured with LHC-8 medium from ThermoFisher in pre-
coated culture dishes with BSA (Fisher), Fibronectin and Collagen I, bovine 
(ThermoFisher).
Expression plasmids
Flag-tagged human CARMA3 has been described previously (Sun and Lin, 2008). HA-
tagged mouse CARMA3 was cloned into pcDNA3 vector. RIG-I, MAVS, TBK1, IKKε and 
IkBα super repressor (SR) plasmids were purchased from Addgene. Flag or Myc-tagged 
BCL10 has been described previously (Blonska et al., 2007). shRNA against CARMA3 or 
BCL10 were purchased from Sigma.
Quantitative real-time PCR and ELISA assay
Quantitative real-time PCR and ELISA assay were performed as recommended by the 
manufacture's protocol.
Luciferase Reporter Assay
Luciferase assay were performed as described previously (Blonska et al., 2005). Briefly, 
293T cells were seeded in triplicates in 12-well plates and transfected with 60 ng of NF-κB-
dependent luciferase (firefly) reporter plasmid and 6 ng of EF1α promoter-dependent 
Renilla luciferase reporter together with 1.5 μg of expression vectors for Carma3, TMEM43 
WT or mutants, or vector controls. The transfected cells were cultured in DMEM containing 
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10% FBS for 16 hr. The cells were harvested and lysed. Luciferase activities in the cell 
lysates were measured by dual-luciferase kit (Promega).
Immunoprecipitation and immunoblotting
These experiments were performed as described previously (Blonska et al., 2005). Briefly, 
1-5 ×106 were seeded, starved for 16 hrs, stimulated with various stimulators for appropriate 
time. The cells were then lysed in a buffer containing 50 mM HEPES (pH 7.4), 250 mM 
NaCl, 1% Nonidet P-40, 1 mM EDTA, 1 mM Na3VO4, 1 mM NaF, 1 mM PMSF, and a 
protease inhibitor mixture (Roche Diagnostics, Mannheim, Germany). The cell lysates were 
subjected to SDS-PAGE and Western blot or immunoprecipitated with appropriate specific 
antibodies. The immunoprecipitates were washed with lysis buffer for 4 times eluted with 2 
× SDS loading buffer. The samples were boiled and separated on 10% SDS-PAGE and 
transferred to nitrocellulose membranes. Immunoblots were incubated with specific primary 
antibodies followed by horseradish peroxidase-conjugated secondary antibodies and were 
developed by the enhanced chemiluminescence method according to the manufacturer's 
protocol (Pierce).
Preparation of nuclear extracts and Electrophoretic mobility shift assay (EMSA)
These experiments were performed as described previously (Blonska et al., 2005). Briefly, 
1-5 ×106 were seeded, starved for 16 hrs, stimulated with various stimulators for appropriate 
time, and nuclear extracts were prepared. Nuclear extracts (5–10 μg) were incubated with 
32P-labeled probes at room temperature for 15 minutes. The samples were separated on a 
native Tris-Borate-EDTA polyacrylamide gel, which was dried at 80°C for 1 hour, and 
exposed to X-ray film.
Lentivirus infection for shRNA knockdown
Lentiviruses were packaged as described previously (Jiang et al., 2011b). Briefly, HEK293T 
were co-transfected with shRNA and packaging vectors encoding VSV-G and ΔVPR using 
the calcium precipitation method. At 48 hours post-transfection, the supernatant was 
collected and applied to infect target cells. The infected were selected by puromycin for 3-4 
days before conduction of experiments.
Isolation of crude mitochondria
These experiments were performed as described previously (Hou et al., 2011). Briefly, cells 
were washed with ice-cold PBS twice and harvested by spinning at 600g for 5 minutes. The 
cells were swollen in hypotonic buffer (10mM Tris-Cl, pH7.5, 10mM KCl, 0.5mM EGTA, 
1.5mM MgCl2, 1mM PMSF, and 1x EDTA-free protease cocktail) for 2.5 minutes at 4°C. 
The swollen cells were homogenized for 40 strokes at 4°C, spun at 600g for 5 minutes. The 
supernatant were transferred to a new tube and spun once more. The resulting supernatant 
was spun to pellet the mitochondria. The mitochondria pellet was resuspended in 
mitochondria resuspending buffer (MRB) (20mM HEPES-KOH, pH7.4, 0.5mM EGTA, 
1mM PMSF, and 1× EDTA-free protease cocktail) containing 0.8M of sucrose and pelleted 
by spinning at 7,000g for 10 minutes. The pellet was resuspended and spun as above. The 
resulting pelleted was resuspended and spun at 10,000g for 10 minutes, and lysed in MRB 
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buffer containing 2% CHAPs on ice for 15 minutes. The mitochondria lysates were mixed 
with 2× loading dye (1 × TBE, 10% glycerol, 4% SDS, and 0.005% bromophenol blue) 
containing no reduction reagents.
Semi-Denaturing Detergent Agarose Gel Electrophoresis (SDD-AGE)
SDD-AGE was performed as described previously with minor modifications (Halfmann and 
Lindquist, 2008). Briefly, 1.5% agarose gel containing 0.1% SDS were prepared in 0.25× 
TAE buffer. The mitochondria lysates in 1× loading dye were loaded into the wells. After 
electrophoresis in the running buffer (0.25× TAE and 0.1% SDS) for 7 hours with a constant 
voltage of 30 V at room temperature, the gel was rinse with water and transferred to 
Immobilon membrane (Millipore) by butterfly transfer in 1× TBS (50mM Tris.Cl, pH7.5, 
150 NaCl). The membrane was then blotted with specific antibody as immunoblotting.6-8-
week-old BALB/c mice (n≥5 per group) were intranasally inoculated with 20 μl of VSV 
(pfu=1×107 per mice) in PBS under isofluorane sedation. Mice serum tissues (lung, brain 
and spleen) were harvested 2 days after infection.
VSV and Influenza virus mice model
6-8-week-old BALB/c mice (n≥5 per group) were intranasally inoculated with 20 μl of 
H1N1 influenza virus (pfu=600 per mice) in PBS under isofluorane sedation. Survival and 
body weight changes were recorded daily for 14 days post-infection (dpi). Animals that 
showed signs of severe disease and weight loss >25% of their initial body weight were 
considered moribund and were humanely sacrificed. Lungs were harvested at 4 days post 
infection. All animal experiments and procedures were conduced under the protocol and 
were approved by the Institutional Animal Care and Use Committee (IACUC) at the 
University of Texas MD Anderson Cancer Center.
VSV plaque assay
The VSV plaque assay protocol was previously described. Briefly, cells were infected with 
VSV (MOI = 3). At 1 h post infection (hpi), the cells were washed twice with serum-free 
DMEM and replenished with complete medium. The supernatant was collected at different 
time points, diluted with serum-free DMEM, and used to infect BHK cells. At 1 hpi, 
medium from the BHK cells was removed and replaced with complete medium containing 
0.5% methylcellulose (Sigma-Aldrich) for 24 to 48 h. BHK cells were fixed in fixation 
solution and stained with crystal violet. Plaques were counted, and titers were calculated as 
PFU per milliliter. Triplicate experiments were performed, and the averages of the virus 
titers were calculated.
Influenza TCID50 Assay
MDCKs were passed in high glucose DMEM (10% FBS, 1% Pen-Strep) in a T175 (a 1:12 
pass dilution every other days) at 37°C. 2×104 cells were seeded in 96 well plates at the 
night before assay with 150 μl of DMEM (FBS, Pen-Strep). Next day morning, Influenza 
samples were thawed on ice and then, homogenized. Transfer 600 μL sample into the 1st 
tube of the dilution series. Serially dilute 184 μL across the tubes. Once samples have been 
diluted across tubes, keep on ice. Add 100 μL of sample to empty wells. Incubate samples at 
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37°C for 1 hour. Aspirate off samples. Add 150 μL of DMEM with typsin (1μg/mL). 
Samples were incubated at 37°C for 3 days. After the 3 days, the media was aspirated off. 
Add 200 μL of a Crystal violet working stock (40 mL 1% Crystal Violet, 80 mL Methanol, 
300 mL H2O). Let the working stock sit for 1 hour. Remove Crystal violet, rinse with water.
Statistical Analysis
The statistical analysis was performed by student t test.
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Highlight
Deficiency of CARMA3 results in the host resistance to RNA viral infection.
CARMA3 positively regulates RIG-I/MAVS-mediated NF-κB activation.
CARMA3 negatively regulates RIG-I/MAVS-mediated TBK1/IRF3 activation.
CARMA3 negatively suppresses MAVS oligomerization in mitochondran.
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Figure 1. CARMA3 played negative roles in antiviral response to influenza/VSV infection in vivo
(A) 6-8-week-old CARMA3 WT and KO mice (n≥5 per group) were intranasally inoculated 
with 600 PFU of IAV per mouse. The weight loss was monitored daily for 14 days and 
plotted. (B-D) Mice were infected as in (A). At 2 days post infection, mouse lungs were 
harvested. Viral load were tittered and plotted. (C) At 4 days post infection, Lungs were 
harvested and cytokine production in mRNA level was measured by quantitative real-time 
PCR. (D) At 4 days post infection, lung fluid was harvested and cytokine production was 
measured by ELISA essay. (E-G) 6-8-week-old CARMA3 WT and KO mice (n≥5 per 
group) were intranasally inoculated with 107 PFU of VSV-GFP per mouse. At 2 days post 
infection, olfactory bulb (OB) were harvested and imaged (E). Viral load in OB were tittered 
and plotted in log scale (F). (G) At one-day post infection, OBs were harvested and cytokine 
production in mRNA level was measured by quantitative PCR. The p values were generated 
by student t test.
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Figure 2. CARMA3 played a positive role in pro-inflammatory response to RNA virus infection
(A-F) Primary CARMA3 WT and KO MEF cells were infected with VSV at MOI = 3 (A-C) 
or transfected with poly(I:C) (D-F) for the indicated time. (A and D) RNA was isolated and 
cytokine production in mRNA level was measured by quantitative real-time PCR, 
normalized to the internal control GAPDH. (B and E) Cytokine production in culture 
supernatants was measured by ELISA assay. (C and F) Nuclear fractions were isolated, and 
EMSA analysis was performed to check NF-κB activation. Oct-1 serves as an internal 
control. (G-J) E1A Immortalized CARMA KO MEF cells were generated and reconstituted 
with HA- tagged CARMA3 or Vector as indicated. These cells were infected with VSV at 
MOI = 3 (G and H) or transfected with poly(I:C) (I and J) for the indicated time. (G and I) 
Cytokine production in culture supernatants was measured by ELISA assay. (H and J) 
Nuclear fractions were isolated, and EMSA analysis was performed to check NF-κB 
activation. Oct-1 serves as an internal control. (K and L) BEAS-2B cells with stable 
knockdown by shRNA against CARMA3 or control were established and infected with VSV 
at MOI = 3 for the indicated time. (K) Nuclear fractions were isolated, and EMSA analysis 
was performed to check NF-κB activation. Oct-1 serves as an internal control. (L) RNA was 
isolated and cytokine production in mRNA level was measured by quantitative real-time 
PCR, normalized to the internal control GAPDH.
Jiang et al. Page 19
Cell Rep. Author manuscript; available in PMC 2018 March 08.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Figure 3. CARMA3 played a negative role in antiviral response to RNA virus infection
(A-H) Primary CARMA3 WT and KO MEF cells were infected with VSV at MOI = 3 (A-C 
and G-H) or transfected with poly(I:C) (D-F) for the indicated time. (A and D) RNA was 
isolated and cytokine production in mRNA level was measured by quantitative real-time 
PCR, normalized to the internal control GAPDH. (B and E) Cytokine production in culture 
supernatants was measured by ELISA analysis. (C, F) Results from Western blotting were 
shown. (G) Viral load in the supernatants of primary MEF cells infected with VSV at 
MOI=3 for 12 hours were tittered and plotted. (H-K) E1A-Immortalized CARMA KO MEF 
cells with the reconstitution of HA-tagged CARMA3 or Vector were infected with VSV at 
MOI = 3 (H-I) or transfected with poly(I:C) (J and K) for the indicated time. (H and J) 
Cytokine production in culture supernatants was measured by ELISA assay. (I and K) 
Results from Western blotting were shown. (L and M)) BEAS-2B cells with stable 
knockdown by shRNA against CARMA3 or Control were established and infected with 
VSV at MOI = 3 for the indicated time. (L) Results from Western blotting were shown. (M) 
RNA was isolated and cytokine production in mRNA level was measured by quantitative 
real-time PCR, normalized to the internal control GAPDH.
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Figure 4. BCL10 played a positive role in pro-inflammatory response and a negative role in anti-
viral response to VSV infection and poly (I:C) treatment
(A-E) Primary BCL10 WT and KO MEF cells were infected with VSV at MOI = 3 (A-C) or 
transfected with poly (I: C) (D-E) for the indicated time. (A-B and D-E) RNA was isolated 
and cytokine production in mRNA level was measured by quantitative real-time PCR, 
normalized to the internal control GAPDH (A-B and D-E). (C) The cells were harvested, 
lysed and subjected to western blotting analysis. (F) 6-8-week-old of BCL10 WT and KO 
mice (n≥5 per group) were intranasally inoculated with 107 PFU of VSV-GFP per mouse. At 
2 days post infection, olfactory bulbs were harvested and viral load in OB were tittered and 
plotted in log scale.
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Figure 5. CARMA3 functions downstream of MAVS but upstream of TBK1 and IKKε
(A and B) Primary WT MEF cells were pretreated with NF-κB translocation inhibitor (NF-
κBi) for 1 hour before VSV infection. Results from EMSA analysis (A) and western blotting 
(B) were shown. (C and D) E1A immortalized CARMA3 KO cells with reconstitution of 
CARMA3 were transfected with IkBα super repressor (SR) or vector control. At 48 hours 
post transfection, the cells were infected with VSV for the indicated time. Results from 
EMSA analysis (C) and western blotting D) were shown. (E) Primary WT MEF cells were 
pretreated with CHX for 1 hour before transfection with poly (I:C). Results from western 
blotting were shown. (F-K) HEK293T cells were stably knocked down with shRNA against 
GFP, CARMA3 (C3) or BCL10 (B10). These cells were co-transfected with MAVS (F and 
I), TBK1 (G and J), or IKKε (H and K) together with IFNβ-Luc and R-Luc (F, G and H), or 
together with NF-κB-Luc and R-Luc (I, J and K). Luciferase assay were performed at 18 
hours post transfection. R-Luc activity serves as internal control.
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Figure 6. CARMA3 inducibly interacts with MAVS and functions to interrupt the interaction 
between MAVS and RIG-I
(A) HEK293T cells were transfected with HA-tagged CARMA3 alone (lane 1), or together 
with Flag-tagged MAVS (lane 2) or Flag-tagged RIG-I (lane 3). At 18 hours post 
transfection, the cells were lysed and the lysates were immunoprecipitated with anti-Flag 
M2 agarose beads. The immunoprecipitates were subjected to western blotting. The black 
solid arrows point to the band(s) of the protein as indicated. (B) HEK293T cells were 
Transfected with Flag-tagged CARMA3 (lane 3) or Flag-tagged BCL10 (lane 2) or together 
(lane 1). The lysates from lane 2 and 3 were immunoprecipitated with anti-Flag M2 agarose 
beads. The lysates from lane 1 were immunoprecipitated with protein A agarose beads and 
served as negative control. The black solid arrows point to the band(s) of the protein as 
indicated. (C and D) E1A-immortalized CARMA KO MEF cells with the reconstitution of 
HA-tagged CARMA3 were infected with VSV for the indicated time. The cells were lysed 
and the lysates were immunoprecipitated with (C) anti-BCL10 antibody or normal IgG 
control or (D) anti-HA antibody or normal IgG control. The immunoprecipitates were 
subjected to western blotting. (E) Primary BCL10 Het and KO MEF or (F) E1A-
immortalized CARMA KO MEF cells with the reconstitution of HA-tagged CARMA3 or 
Vector were infected with VSV for the indicated time. The cells were lysed and the lysates 
were immunoprecipitated with (E) anti-CARMA3 antibody or IgG control, or (F) anti-
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BCL10 antibody or IgG control. The immunoprecipitates were subjected to Western 
blotting.
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Figure 7. CARMA3 undergoes signal-dependent polyubiquitination and degradation
(A) HEK293T cells were transfected with RIG-I alone (lane 1 and 4) or together with Flag-
tagged CARMA3 at indicated dose (lanes 2-3 and 5-6). Crude mitochondria were isolated at 
18 hours post transfection. Whole cell lysates and lysates from aliquots of mitochondria 
were subjected to Western blotting (upper panel). The rest of mitochondrial lysates were 
subjected to SDD-AGE analysis (bottom panel). * indicates the CARMA3 protein band. 
Short and long in parentheses represent the short exposure or long exposure. (B and C) 
Primary CARMA3 WT and KO MEF cells (B) or E1A immortalized CARMA3 KO with the 
reconstitution of CARMA3 or vector (C) was infected with VSV for the indicated time. 
Crude mitochondria were isolated and lysates from aliquots of mitochondria were subjected 
to Western blotting (bottom panel). The rest of mitochondria lysates were subjected to SDD-
AGE analysis (upper panel). (D) E1A immortalized CARMA3 KO MEF cells with the 
reconstitution of HA-tagged CARMA3 or vectors were infected with VSV for the indicated 
time. The cells were lysed and the lysates were immunoprecipitated with anti-HA antibody. 
The immunoprecipitates were subjected to Western blotting. (B) E1A immortalized 
CARMA3 KO with the reconstitution of HA-tagged CARMA3 were pretreated with MG132 
or CHX one hour before infection with VSV as indicated. The cells were harvested at 6 
hours post infection, lysed and subjected to Western blotting. (F)) E1A immortalized 
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CARMA3 KO with the reconstitution of HA-tagged CARMA3 were infected with VSV for 
the indicated time. MG132 were added to the sample in lane 4 at 2 hours post infection. The 
cells were lysed and the lysates were immunoprecipitated with anti-HA antibody (lanes 2-5) 
or normal IgG control (lane 1). The immunoprecipitates were subjected to Western blotting. 
(G) E1A immortalized CARMA3 KO MEF cells with the reconstitution of HA-tagged 
CARMA3 was infected with VSV for the indicated time. The cells were lysed and the 
lysates were subjected to Western blotting.
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